Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 6:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Patient-Specific Protocol Clear all
Completed Phase 1Phase 2 Interventional

VX-853 in Treating Patients With Solid Tumors Who Are Receiving Liposomal Doxorubicin

NCT00004030
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
VX-853, pegylated liposomal doxorubicin hydrochloride
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2001
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 23, 2011 · Synced Sep 12, 2026, 6:13 AM EDT
Completed Phase 3 Interventional Results available

A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors

NCT02795767
View directory record Official record
Conditions
Hemophilia A
Interventions
Emicizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Up to 17 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
8
States / cities
Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2021 · Synced Sep 12, 2026, 6:13 AM EDT
Completed Phase 1 Interventional

Hydroxychloroquine and Temozolomide in Treating Patients With Metastatic or Unresectable Solid Tumors

NCT00714181
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
hydroxychloroquine, temozolomide, TdT-mediated dUTP nick end labeling assay, western blotting, electron microscopy, high performance liquid chromatography, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, mass spectrometry, pharmacological study
Drug · Genetic · Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 120 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Sep 12, 2026, 6:13 AM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema

NCT03481634
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Brolucizumab, Aflibercept
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
566 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
39
States / cities
Phoenix, Arizona • Beverly Hills, California • La Jolla, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2023 · Synced Sep 12, 2026, 6:13 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies

NCT04959175
View directory record Official record
Conditions
Hematologic Neoplasms
Interventions
Mycophenolate Mofetil, Allogeneic HSCT, Fludarabine, Sirolimus, Filgrastim, Cyclophosphamide, Mesna, Total Body Irradiation (TBI)
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 85 Years
Enrollment
320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
2
States / cities
Bethesda, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 12, 2026, 6:13 AM EDT
Completed Phase 1 Interventional

SR-45023A in Treating Patients With Locally Advanced or Metastatic Solid Tumors

NCT00004049
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
apomine
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 120 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Sep 12, 2026, 6:13 AM EDT
Completed Phase 3 Interventional

Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment

NCT00006348
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Nausea and Vomiting, Precancerous Condition, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
ondansetron, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
12
States / cities
Scottsdale, Arizona • Urbana, Illinois • Des Moines, Iowa + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2016 · Synced Sep 12, 2026, 6:13 AM EDT
Completed Phase 1 Interventional

Calcitriol and Gefitinib With or Without Dexamethasone in Treating Patients With Advanced Solid Tumors

NCT00084708
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
calcitriol, dexamethasone, gefitinib
Dietary Supplement · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 12, 2014 · Synced Sep 12, 2026, 6:13 AM EDT
Recruiting Not applicable Interventional

VCOM Pain Free Research Collaborative

NCT06533345
View directory record Official record
Conditions
Chronic Pain
Interventions
Behavior Change Coaching, Nutrition, Autonomic Recalibration, Dry Needling, Osteopathic Manipulative Treatment, Counseling Psychology, Multiple Treatments
Behavioral · Other · Procedure
Lead sponsor
Edward Via Virginia College of Osteopathic Medicine
Other
Eligibility
21 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Auburn, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Sep 12, 2026, 6:13 AM EDT
Completed Phase 1 Interventional Results available

A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies

NCT02327169
View directory record Official record
Conditions
Advanced Nonhematologic Malignancies
Interventions
MLN2480, MLN0128, Alisertib, Paclitaxel, Cetuximab, Irinotecan
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
5
States / cities
Boston, Massachusetts • Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Sep 12, 2026, 6:13 AM EDT
Completed Phase 1 Interventional

Irinotecan Followed by Fluorouracil in Treating Patients With Advanced Solid Tumors

NCT00024141
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
fluorouracil, irinotecan hydrochloride
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 6, 2011 · Synced Sep 12, 2026, 6:13 AM EDT
Completed Phase 1 Interventional

Anakinra in Treating Patients With Metastatic Cancer Expressing the Interleukin-1 Gene

NCT00072111
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
anakinra
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Sep 12, 2026, 6:13 AM EDT
Completed No phase listed Observational

Hearing Loss and Dizziness in Patients Receiving Oxaliplatin for Solid Tumors

NCT00305799
View directory record Official record
Conditions
Neurotoxicity, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
management of therapy complications
Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 23, 2014 · Synced Sep 12, 2026, 6:13 AM EDT
Not listed Not applicable Interventional

Frequency of Screening and SBT Technique Trial

NCT02399267
View directory record Official record
Conditions
Critically Ill
Interventions
Once daily screening, Twice daily screening, PS SBTs, T-piece SBTs
Procedure
Lead sponsor
Unity Health Toronto
Other
Eligibility
16 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
2
States / cities
Long Beach, California • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Sep 12, 2026, 6:13 AM EDT
Terminated No phase listed Observational Results available

Use of Patient-Controlled Analgesia in Acute Pancreatitis

NCT04816877
View directory record Official record
Conditions
Acute Pancreatitis
Interventions
Opioid
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Sep 12, 2026, 6:13 AM EDT
Completed Phase 1 Interventional

Paricalcitol and Gemcitabine in Treating Patients With Advanced Cancer

NCT00217477
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
gemcitabine hydrochloride, paricalcitol
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Dec 8, 2014 · Synced Sep 12, 2026, 6:13 AM EDT
Completed Phase 1 Interventional

Warfarin and Vatalanib in Treating Patients With Advanced Solid Tumors

NCT00091299
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
warfarin
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2020 · Synced Sep 12, 2026, 6:13 AM EDT
Completed Phase 1 Interventional

Irinotecan Plus ICI D1694 in Treating Patients With Advanced Solid Tumors

NCT00002902
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
irinotecan hydrochloride, raltitrexed
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 12, 2019 · Synced Sep 12, 2026, 6:13 AM EDT
Terminated Phase 1 Interventional

Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors

NCT00112619
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Carcinoma of Unknown Primary, Leukemia, Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
topotecan hydrochloride
Drug
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
3 Years to 21 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
11
States / cities
San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2011 · Synced Sep 12, 2026, 6:13 AM EDT
Completed Phase 1 Interventional

Calcitriol Plus Paclitaxel in Treating Patients With Advanced Solid Tumors

NCT00009802
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
calcitriol, paclitaxel
Dietary Supplement · Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Sep 12, 2026, 6:13 AM EDT
Completed Phase 2 Interventional

Paclitaxel in Treating Women With Recurrent Solid Tumors

NCT00003130
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
paclitaxel
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2006
U.S. locations
34
States / cities
La Jolla, California • San Francisco, California • Wilmington, Delaware + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2016 · Synced Sep 12, 2026, 6:13 AM EDT
Completed Phase 1Phase 2 Interventional

Extracranial Stereotactic Radiosurgery in Treating Patients With Solid Tumors

NCT00311597
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Radiosurgery
Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Sep 12, 2026, 6:13 AM EDT
Completed Not applicable Interventional Results available

Neuromuscular Intervention Targeted to Mechanisms of ACL Load in Female Athletes

NCT03190889
View directory record Official record
Conditions
Rehabilitation, ACL Reconstruction
Interventions
HOME, TNMT
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
13 Years to 30 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
4
States / cities
Flowery Branch, Georgia • Minneapolis, Minnesota • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Sep 12, 2026, 6:13 AM EDT
Completed Phase 1 Interventional

R115777 Plus Topotecan in Treating Patients With Advanced Solid Tumors

NCT00005990
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
tipifarnib, topotecan hydrochloride
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 8, 2012 · Synced Sep 12, 2026, 6:13 AM EDT